Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02337205 · ClinicalTrials.gov registry record · Phase 1
Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis
A Phase 1 study of Actinic Keratosis, sponsored by Athenex.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT02337205: Completed Phase 1 study of Actinic Keratosis, sponsored by Athenex.
NCT02337205 is a Phase 1 study of Actinic Keratosis that has completed, run by Athenex. The registered enrollment target is 29 participants, below the 187-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02337205, a Phase 1 study of Actinic Keratosis, has completed, sponsored by Athenex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 study to access the safety and tolerability of KX2-391 ointment in subjects who have Actinic Keratosis. This study will also access the amount of KX2-391 drug that enters the blood stream through dermal application of the ointment.
Primary Outcome
Safety assessments will consist of determining and recording all AEs (including for both increasing and decreasing severity) and SAEs; laboratory evaluation for hematology, blood chemistry, and urine analytes; periodic measurement of vital signs and ECGs; and the performance of physical examinations as detailed in Table 3 of the protocol.
Conditions Studied
Interventions
- DRUG KX2-391 Ointment
Study Locations (1)
Texas
- DermResearch, Inc. - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
What the finished NCT02337205 record still lists
NCT02337205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 187-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Actinic Keratosis appearing as the primary indexed condition, and to 1 intervention - of which KX2-391 Ointment is the first listed.
NCT02337205 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02337205 about?
NCT02337205 is a clinical study titled "Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis". This is a phase 1 study to access the safety and tolerability of KX2-391 ointment in subjects who have Actinic Keratosis. This study will also access the amount of KX2-391 drug that enters the blood stream through dermal application of the ointment.
What is the current status of trial NCT02337205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2014-12. Estimated completion is 2016-03.
What conditions does trial NCT02337205 study?
This clinical trial studies the following conditions: Actinic Keratosis.
What interventions are being tested in trial NCT02337205?
The interventions under investigation include: KX2-391 Ointment (DRUG).
Who is sponsoring clinical trial NCT02337205?
This trial is sponsored by Athenex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02337205 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02337205's enrollment target sits among peer trials
29 14th of 16 higher than 3 of 16 other Actinic Keratosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Actinic Keratosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy
RECRUITING · Phase 1
-
A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
COMPLETED · Phase 1
-
PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects
COMPLETED · Phase 1
-
The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans
RECRUITING · Phase 2
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
ACTIVE NOT RECRUITING · Phase 3
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia